figure s1. analysis of immune‑associated gene expression
TRANSCRIPT
Figure S1. Analysis of immune‑associated gene expression levels regulated by DDX41. (A) Top ten GO terms of upregulated gene sets. (B) Top ten KEGG pathways of downregulated gene sets. (C) Hierarchical clustering of the expression of immune‑associ-ated differentially expressed genes regulated by DDX41 overexpression in HeLa cells compared with Ctrl. GO, Gene Ontology; KEGG, Kyoto Encyclopedia of Genes and Genomes; DDX41, DEAD‑box helicase 41; Ctrl, control.
Figure S2. Kaplan‑Meier curves of DDX41 upregulated genes in patients with cervical cancer. (A) Survival analysis of two genes in the Gene Expression Profiling Interactive Analysis databases of cervical and endocervical squamous carcinoma (cut‑off point based on the median method). (B) Images of the DDX41 distribution (n=3). DDX41, DEAD‑box helicase 41; HR, hazard ratio.
Figure S3. Schematic diagrams depicting the structures of AS1 (purple) and AS2 (green). Boxes indicate exon sequences; hori-zontal line indicates intron sequences. RNA‑seq quantification and qPCR validation of ASEs. The changed ratio of ASEs in RNA‑seq were calculated using the formula: AS1 junction reads/AS1 junction reads + AS2 junction reads. The altered ratio of ASEs in qPCR was calculated using the formula: AS1 transcripts level/AS2 transcripts level. Con, control; OE‑DDX41, overex-pression DEAD‑box helicase 41; RNA‑seq, RNA‑sequencing; qPCR, quantitative PCR.
Tabl
e SI
. Prim
ers u
sed
in re
vers
e tra
nscr
iptio
n-qu
antit
ativ
e PC
R.
A, O
vere
xpre
ssio
n
Gen
e Fo
rwar
d pr
imer
(5'→
3')
Rev
erse
prim
er (5
'→3'
)
DD
X41
GTA
TCC
CA
CC
AC
CC
ATC
AA
G
AC
CA
GTG
TCTT
GC
CTG
AA
CC
B, D
iffer
entia
lly e
xpre
ssed
gen
es
Gen
e Fo
rwar
d pr
imer
R
ever
se p
rimer
IL12
A AT
TGA
GAT
GG
GA
GG
ATTG
C
AG
AC
ATAT
TGTC
CA
GG
CT
CD
22
GG
CC
TTTT
CC
AC
CTC
ATA
G
GAT
CG
GAT
AC
CC
ATA
GC
CD
177
AC
GG
AG
GC
CA
AG
GA
CC
AG
C
CA
AA
GC
GG
GA
GG
GA
GTT
CSF
2 G
AC
CTG
CC
TAC
AG
AC
CC
G
GG
CC
CTT
GA
GC
TTG
GTG
ASE
LPLG
G
CC
GTC
AG
TCG
AG
TTG
TC
CA
GC
AG
CTA
TGG
AG
ATA
CA
GTN
FRSF
1B
GC
AC
TCG
GG
AA
CA
GA
AC
C
GC
AC
CC
CTC
CTG
CTT
GC
TH
SPA1
A C
GTT
GTC
CC
AA
GG
CTT
CC
C
TGTC
GG
CTC
CG
CTC
TGA
HSP
A1B
GC
TGA
AC
CC
GC
AG
AA
CA
C
TCC
TCG
GG
GTA
GA
ATG
CC
HSP
A6
CG
GTG
CA
GTC
GG
AC
ATG
A
TCTC
CTC
GG
GG
TAG
AA
CG
HLA
-DM
B G
CC
ATC
TTAT
TCTC
CTC
TG
TGG
AA
AG
CA
CC
TGTC
TGT
HLA
-DO
B AT
CC
AC
GG
CC
TGTC
TGC
T G
TGAT
GTG
GG
GAT
GTT
TGH
LA-G
TC
TAC
CC
TGC
GG
AG
ATC
A
CTC
CA
GA
AG
GC
AC
CA
CC
AH
PV18
-E6
ATA
AG
GTG
CC
TGC
GG
TGC
C
TGC
GTC
GTT
GG
AG
TCG
TTC
HPV
18-E
7 G
AG
CA
CG
AC
AG
GA
AC
GA
CT
GG
GC
TGG
TAA
ATG
TTG
ATG
ATH
PV18
-L1
CA
GG
TGG
TGG
CA
ATA
AG
CA
GG
A
TGG
CG
GC
ATG
GG
AA
CTT
TCA
GG
APD
H
GG
TCG
GA
GTC
AA
CG
GAT
TTG
G
GA
AG
ATG
GTG
ATG
GG
ATTT
C
C, A
ltern
ativ
e sp
licin
g ev
ents
Gen
e Fo
rwar
d pr
imer
R
ever
se p
rimer
CFD
A
S1
TGG
AG
GA
CG
CG
GC
CG
AC
GG
G
AG
CA
GG
AG
GTC
GTG
GTC
G
AS2
G
GTC
CC
CA
GG
GG
CC
GA
CG
GG
PGLY
RP1
AS1
C
CA
ATTC
TGG
ATG
AG
GTG
GTA
A
AC
TAC
ATG
GAT
CG
GG
TGC
C
AS2
CC
TCC
TCC
AG
ATC
GG
GTG
CC
NEA
TC3_
A3SS
A
S1
CA
GC
AC
TCA
AC
TCA
AG
CA
G
TAA
AC
AA
ATC
ATC
ATC
TAA
A
S2
TA
GG
TCTC
AA
CAT
CAT
CTA
AN
EATC
3_M
EX
AS1
A
S2
CA
GC
AC
TCA
AC
TCA
AG
CA
AT
AA
ATTG
GTC
ATC
ATC
TAA
TA
GG
TCTC
AA
CAT
CAT
CTA
A
Tabl
e SI
. Con
tinue
d.
C, A
ltern
ativ
e sp
licin
g ev
ents
Gen
e Fo
rwar
d pr
imer
R
ever
se p
rimer
NO
D1
AS1
TA
CG
CTG
AG
TCTG
AG
AA
CA
G
CTA
CTG
CA
AC
GC
CTG
CTC
A
S2
GA
CC
TCTG
CC
CTG
AG
AA
CA
GZC
3HAV
1 A
S1
AA
GC
GG
AC
AA
CC
CTT
AC
A
CTT
GTT
AA
CG
ATTC
TTTA
TC
AS2
TC
TGC
TCA
GTA
TTC
TTTA
TCIF
ITM
1 A
S1
GA
CA
AG
TGA
GC
CA
GA
AG
ATG
TT
GA
AC
AG
GG
AC
CA
GA
CG
A
S2
TCC
CC
AA
AG
CC
CA
GA
AG
ATG
TA
NK
A
S1
TGG
AG
AA
GA
GA
CC
TGTC
ATT
CTG
CC
GG
AA
GG
CTT
CAT
A
AS2
C
AA
AC
GA
GA
GA
CC
TGTC
ATT
NLR
X1-1
A
S1
CTG
CC
TGA
AG
GA
CA
GA
AG
TC
TCG
CTG
GA
GTG
CTC
TTC
T
AS2
G
CA
GC
CG
CG
GG
AC
AG
AA
GTC
N
LRX1
-2
AS1
C
CG
CTG
CC
AG
GA
CA
GA
AG
TC
TCG
CTG
GA
GTG
CTC
TTC
T
AS2
G
CG
GG
CG
GA
GG
AC
AG
AA
GTC
C
HID
1 A
S1
GTC
CA
GA
GG
GC
TGC
ATG
TCA
A
GC
CC
TGC
CC
AG
TCC
CC
TGT
A
S2
GG
GTG
GA
AAT
CTG
CAT
GTC
A
Table SII. Summary of RNA-sequencing reads used.
Sample Raw reads Clean reads Paired-end reads Total mappeda Total uniquely mappedb Splice readsc
DDX41_1st 82863280 79800968 36767980 69908587 67381207 27164706 (90.62%) (96.38%) (40.31%)DDX41_2nd 87014568 83839108 36659857 73033917 70304018 27599947 (90.06%) (96.26%) (39.26%)Ctrl_1st 79477058 76304335 38572300 67176989 64837664 26594525 (91.35%) (96.52%) (41.02%)Ctrl_2nd 79182390 76036977 40548512 66508088 64019512 25577536 (90.71%) (96.26%) (39.95%)
aPercentage of paired-end reads mapped to the genome. bPercentage of unique reads mapping out of the total mapped reads. cPercentage of uniquely mapped reads mapped to splice site. DDX41, DEAD-box helicase 41; Ctrl, control.
Table SIII. Numbers of genes expressed in each sample.
Expressed genes ‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑Sample FPKM>0 FPKM≥1
OECtrl_1st 24,499 13,173OECtrl_2nd 25,045 13,164DDX41_1st 24,618 12,892DDX41_2nd 24,440 12,885Totalgenes 28,914
OE,overexpression;Ctrl,control;DDX41,DEAD-boxhelicase41;FPKM,fragmentsperkilobaseoftranscriptpermillion.